Evidence map›Paper›PMID 24840307›Full record

ArticlePloS one2014

Antibacterial activity of THAM Trisphenylguanide against methicillin-resistant Staphylococcus aureus.

Alan J Weaver, Joyce B Shepard, Royce A Wilkinson, Robert L Watkins, Sarah K Walton, Amanda R Radke, Thomas J Wright, Milat B Awel, Catherine Cooper, Elizabeth Erikson and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Antimicrobial activity of the toxin VdTX-I from the spiderBiochemistry and biophysics reports · 2015
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Alan J WeaverDepartment of Chemistry & Biochemistry, Montana State University, Bozeman, Montana, United States of America.
Joyce B ShepardDepartment of Chemistry & Biochemistry, Montana State University, Bozeman, Montana, United States of America.
Royce A WilkinsonDepartment of Chemistry & Biochemistry, Montana State University, Bozeman, Montana, United States of America; Department of Microbiology & Immunology, Montana State University, Bozeman, Montana, United States of America.
Robert L WatkinsDepartment of Microbiology & Immunology, Montana State University, Bozeman, Montana, United States of America.
Sarah K WaltonDepartment of Chemistry & Biochemistry, Montana State University, Bozeman, Montana, United States of America.
Amanda R RadkeDepartment of Chemistry & Biochemistry, Montana State University, Bozeman, Montana, United States of America.
Thomas J WrightDepartment of Chemistry & Biochemistry, Montana State University, Bozeman, Montana, United States of America.
Milat B AwelDepartment of Chemistry & Biochemistry, Montana State University, Bozeman, Montana, United States of America.
Catherine CooperDepartment of Microbiology & Immunology, Montana State University, Bozeman, Montana, United States of America.
Elizabeth EriksonDepartment of Microbiology & Immunology, Montana State University, Bozeman, Montana, United States of America.
Mohamed E LabibAdvanced BioDevices, Princeton, New Jersey, United States of America.
Jovanka M VoyichDepartment of Microbiology & Immunology, Montana State University, Bozeman, Montana, United States of America.
Martin TeintzeDepartment of Chemistry & Biochemistry, Montana State University, Bozeman, Montana, United States of America.
Montana State University · US

Funding

MT INBRE RESEARCH COREP20RR016455 · NCRR · MONTANA STATE UNIVERSITY - BOZEMAN · PI HARMSEN, ALLEN G · 2001 to 2011
$34.4M
VIRUSES: FROM PARTICLES TO PROTEOMICSP20RR020185 · NCRR · MONTANA STATE UNIVERSITY - BOZEMAN · PI MEISSNER, NICOLE · 2004 to 2011
$17.0M
SYSTEMS BIOLOGY OF HOST-PATHOGEN INTERACTIONSP20RR024237 · NCRR · MONTANA STATE UNIVERSITY - BOZEMAN · PI SINGEL, DAVID J · 2008 to 2011
$8.1M
Single and multi-component biguanide-based microbicidesU19AI076965 · NIAID · NOVAFLUX BIOSCIENCES, INC. · PI LABIB, MOHAMED E · 2007 to 2007
$867k
NCRR NIH HHS P20 RR016455NCRR NIH HHS P20RR016455NCRR NIH HHS P20 RR020185NCRR NIH HHS P20RR020185NCRR NIH HHS P20 RR024237NCRR NIH HHS P20RR024237NIAID NIH HHS AI076965NIAID NIH HHS U19 AI076965
6 · The paper itself

Abstract

This study investigated the potential antibacterial activity of three series of compounds synthesized from 12 linear and branched polyamines with 2-8 amino groups, which were substituted to produce the corresponding guanides, biguanides, or phenylguanides, against Acinetobacter baumannii, Enterococcus faecalis, Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus. Antibacterial activity was measured for each compound by determining the minimum inhibitory concentration against the bacteria, and the toxicity towards mammalian cells was determined. The most effective compound, THAM trisphenylguanide, was studied in time-to-kill and cytoplasmic leakage assays against methicillin-resistant Staphylococcus aureus (MRSA, USA300) in comparison to chlorhexidine. Preliminary toxicity and MRSA challenge studies in mice were also conducted on this compound. THAM trisphenylguanide showed significant antibacterial activity (MIC ∼1 mg/L) and selectivity against MRSA relative to all the other bacteria examined. In time-to-kill assays it showed increased antimicrobial activity against MRSA versus chlorhexidine. It induced leakage of cytoplasmic content at concentrations that did not reduce cell viability, suggesting the mechanism of action may involve membrane disruption. Using an intraperitoneal mouse model of invasive MRSA disease, THAM trisphenylguanide reduced bacterial burden locally and in deeper tissues. This study has identified a novel guanide compound with selective microbicidal activity against Staphylococcus aureus, including a methicillin-resistant (MRSA) strain.

Indexed as

Acinetobacter baumanniiAnimalsAnti-Bacterial AgentsBiguanidesEnterococcus faecalisEscherichia coliGuanidinesMethicillin-Resistant Staphylococcus aureusMiceMicrobial Sensitivity TestsMolecular StructurePseudomonas aeruginosaAnti-Bacterial AgentsBiguanidesGuanidinesphenylguanidine

Identifiers

PMID24840307
PMCPMC4026384
OpenAlexW1968949925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.